menu
    • menu
    [{"orgOrder":0,"company":"Natera","sponsor":"Massachusetts General Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Collaboration","leadProduct":"Ribociclib","moa":"||Cyclin-dependent kinase 6 | Cyclin-dependent kinase 4","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Natera \/ Massachusetts General Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Massachusetts General Hospital"},{"orgOrder":0,"company":"Natera","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"Genentech","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Atezolizumab","moa":"Programmed cell death 1 ligand 1","graph1":"Oncology","graph2":"Phase III","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natera \/ Genentech","highestDevelopmentStatusID":"10","companyTruncated":"Natera \/ Genentech"},{"orgOrder":0,"company":"Natera","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2024","type":"Inapplicable","leadProduct":"Trastuzumab Deruxtecan","moa":"Receptor protein-tyrosine kinase erbB-2 | DNA topoisomerase I","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natera \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Undisclosed"},{"orgOrder":0,"company":"Natera","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cytotoxic Drug","year":"2023","type":"Inapplicable","leadProduct":"Fluorouracil","moa":"RNA | DNA | Thymidylate synthase||Thymidylate synthase | RNA | DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"6","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"Washington University School of Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Vaccine","year":"2024","type":"Inapplicable","leadProduct":"Synthetic Long Peptide Personalized Cancer Vaccine","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"6","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"Natera","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"PD-1","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Natera \/ Natera","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ Natera"},{"orgOrder":0,"company":"Natera","sponsor":"MEDSIR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Collaboration","leadProduct":"Giredestrant","moa":"Estrogen receptor alpha","graph1":"Oncology","graph2":"Phase II","graph3":"Natera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Natera \/ MEDSIR","highestDevelopmentStatusID":"8","companyTruncated":"Natera \/ MEDSIR"}]

    Find Clinical Drug Pipeline Developments & Deals by Natera

    Menu

    Natera

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Giredestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : MEDSIR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Natera, MEDSIR Collaborate on MiRaDoR Trial in Breast Cancer

                            Details : The collaboration aims to advance the clinical development of Giredestrant, a miscellaneous product targeting estrogen receptor alpha in breast cancer.

                            Product Name : GDC-9545

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            December 12, 2025

                            Lead Product(s) : Giredestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : MEDSIR

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Circulating Tumor DNA Response In Urothelial Cancer

                            Details : Pembrolizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase II clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            September 19, 2025

                            Lead Product(s) : Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Oklahoma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Synthetic Long Peptide Personalized Cancer Vaccine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

                            Details : Synthetic Long Peptide Personalized Cancer Vaccine is a Vaccine drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Inapplicable

                            July 31, 2024

                            Lead Product(s) : Synthetic Long Peptide Personalized Cancer Vaccine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Washington University School of Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natera Announces DECIPHER: Phase II Trial in Gastroesophageal Cancer

                            Details : Enhertu (trastuzumab deruxtecan) is a HER2-directed antibody-drug conjugate which is being evaluated in phase 2 clinical trials for the treatment of patients with Gastroesophageal Cancer.

                            Product Name : Enhertu

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            June 27, 2024

                            Lead Product(s) : Trastuzumab Deruxtecan

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : UNICANCER

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Decreasing Treatment for Metastatic HER2-Positive Breast Cancer With Undectable Cancer Levels in Blood Tests.

                            Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Breast Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            June 10, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : UNICANCER

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : University of California, Irvine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)

                            Details : 5-Fluorouracil is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Gastroesophageal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            February 17, 2023

                            Lead Product(s) : Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : University of California, Irvine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Natera and Genentech Initiate Phase III Trial Using Signatera as a Companion Diagnostic for Atezolizumab in Mu...

                            Details : First patient has been screened in a new phase III clinical trial that uses Signatera, as a companion diagnostic to identify muscle-invasive urothelial carcinoma patients eligible for investigational treatment with Genentech’s cancer immunotherapy drug...

                            Product Name : Tecentriq

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            March 10, 2021

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Genentech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II Randomized Therapeutic Optimization Trial for Subjects With Refractory Metastatic Colorectal Cancer...

                            Details : This drug candidate is currently being evaluated in phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 08, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : University of Florida

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder ...

                            Details : Atezolizumab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Urinary Bladder Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            December 09, 2020

                            Lead Product(s) : Atezolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Recipient : F. Hoffmann-La Roche

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed

                            Natera

                            U.S.A arrow
                            BIO Partnering at JPM
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ribociclib,Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Natera Enters Collaboration with Massachusetts General Hospital for a Prospective Randomized Clinical Trial in...

                            Details : The collaboration is focused on a investigator-initiated multi-center, Phase II randomized clinical trial of Ribociclib (Kisqali®), a CDK4/6 inhibitor, for the treatment of ER-positive breast cancer (LEADER).

                            Product Name : Kisqali

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            August 27, 2020

                            Lead Product(s) : Ribociclib,Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Massachusetts General Hospital

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.